uniQure (QURE) Expected to Release Quarterly Earnings on Wednesday

uniQure (NASDAQ:QURE) is expected to be posting its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect uniQure to post earnings of ($0.8223) per share and revenue of $5.4490 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Stock Performance

NASDAQ QURE opened at $38.97 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -11.20 and a beta of 0.90. The firm has a 50 day simple moving average of $35.94 and a 200-day simple moving average of $25.68. uniQure has a one year low of $8.73 and a one year high of $71.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on QURE shares. Leerink Partners increased their target price on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Royal Bank Of Canada upped their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. HC Wainwright lifted their target price on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $64.17.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 164,429 shares of uniQure stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the transaction, the chief executive officer owned 558,810 shares in the company, valued at $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the transaction, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. This trade represents a 44.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 433,229 shares of company stock valued at $17,944,799 over the last ninety days. 4.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently bought and sold shares of the business. Woodline Partners LP raised its stake in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of uniQure during the 2nd quarter worth about $497,000. Marshall Wace LLP increased its holdings in shares of uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of uniQure in the 2nd quarter valued at about $540,000. Finally, Ameriprise Financial Inc. raised its position in shares of uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.